MFN ‘Conversations’ Have Started, Pfizer’s Bourla Says, But There’s Not Much There There

We’re going to talk about Robert Kennedy today. Here’s the tweet announcing his nomination. Here’s reaction from PhRMA and BIO. I haven’t seen anything from the American Hospital Association or

Minnesota 340B Watch Update. I emailed the nice folks at the Minnesota Department of Health about where their 340B transparency report, and I quickly received a brief reply: “We hope

  Inflection Point The thorniest problem in biopharmaceuticals is the growing conflict between cost-effectiveness and budget impact. In other words, we increasingly have weapons against disease that are, objectively and